Mereo BioPharma Strengthens Management Team; Appoints John Lewicki, PhD, as Chief Scientific Officer and Ann Kapoun, PhD, as SVP of Translational Research and Development Jun 30, 2020 07:00AM
Mereo BioPharma Announces Financial Results for the Year Ended December 31, 2019 Jun 16, 2020 07:00AM
Mereo BioPharma Announces Completion of $70 Million Private Placement Jun 4, 2020 07:00AM
Business Update and Directorate Change Mar 27, 2020 08:00AM
Mereo BioPharma Announces Positive Feedback from Type B End-of-Phase 2 Meeting with the FDA and Outlines Pivotal Phase 3 Pediatric Study Design for Setrusumab in Osteogenesis Imperfecta Feb 28, 2020 07:00AM


Feb 19, 2020 03:00AM Mereo BioPharma Announces Equity Investment of $3 Million from New U.S. Institutional Investor
Feb 12, 2020 08:00AM Mereo BioPharma Announces Update on Distribution Related to Contingent Value Rights Following Recent Oncologie Licensing Agreement for Navicixizumab
Feb 10, 2020 07:00AM Mereo BioPharma Enters into a $5 Million Convertible Equity Financing with Novartis and Announces a Securities Purchase Agreement with Aspire Capital Fund, LLC for up to $28 Million
Jan 14, 2020 07:00AM Mereo BioPharma Announces Additional Positive Data from Phase 2b ASTEROID Study of Setrusumab in Adults with Osteogenesis Imperfecta and Provides Update on Regulatory Progress
Jan 13, 2020 07:00AM Mereo BioPharma and Oncologie Enter into Global Licensing Agreement for Navicixizumab
Jan 13, 2020 07:00AM Mereo BioPharma and Oncologie Enter into Global Licensing Agreement for Navicixizumab
Nov 11, 2019 06:30AM Mereo BioPharma’s Setrusumab Demonstrates Dose-Dependent Bone Building and Trend in Fracture Reduction in Phase 2b ASTEROID Study in Adults with Osteogenesis Imperfecta
Oct 7, 2019 08:02AM UPDATE: Mereo BioPharma (MREO) Receives FDA Fast Track Designation for Navicixizumab for Treatment of Heavily Pretreated Ovarian Cancer
Oct 7, 2019 08:00AM Mereo BioPharma Receives FDA Fast Track Designation for Navicixizumab for the Treatment of Heavily Pretreated Ovarian Cancer
Sep 17, 2019 07:00AM Mereo BioPharma Announces Interim Financial Results for the Six Months Ended June 30, 2019 and Provides Corporate Update
Sep 10, 2019 08:00AM Mereo BioPharma to Announce Interim Financial Results for the Six Months Ended June 30, 2019 and Provide Corporate Update on September 17, 2019
Sep 4, 2019 08:00AM Mereo BioPharma Announces Setrusumab 6-Month Phase 2b Data in Osteogenesis Imperfecta Selected for Late-Breaking Oral Presentation at the American Society for Bone and Mineral Research (ASBMR) 2019 An
Jul 16, 2019 08:00AM Mereo BioPharma Appoints Richard Francis as Head of Pharmaceutical Development
Jul 15, 2019 08:06AM Mereo BioPharma (MREO) Announces Successful Type B Meeting with FDA, Outlines Accelerated Approval Pathway for Navicixizumab
Jul 15, 2019 08:00AM Mereo BioPharma Announces Successful Type B Meeting with U.S. FDA and Outlines Accelerated Approval Pathway for Navicixizumab in Advanced Ovarian Cancer
Jun 13, 2019 08:00AM Mereo BioPharma Group plc (“Mereo” or the “Company” or the “Group”) Update on Etigilimab (TIGIT) Partnership
May 30, 2019 02:00AM Mereo BioPharma Group plc Announces Positive Early 6 Month Data from the Open Label Arm of the Phase 2b Clinical Study in Adult Patients with Type I, III or IV Osteogenesis Imperfecta Treated with the
May 3, 2019 12:09PM Mereo BioPharma Group plc (“Mereo” or the “Company” or the “Group”) Intention to Purchase Shares by Trustee of Employee Benefit Trust
Apr 26, 2019 08:00AM Mereo Biopharma to Announce Preliminary Results for the Full Year 2018 and Host Conference Call on April 29, 2019
Apr 24, 2019 09:30AM Mereo BioPharma Group plc ("Mereo" or the "Company" or the "Group") Admission to trading on AIM of New Shares and initiation of trading on Nasdaq of American Depositary S
Apr 23, 2019 09:28AM Mereo BioPharma Group plc ("Mereo" or the "Company" or the "Group") Completion of the Merger with OncoMed Pharmaceuticals, Inc.
Apr 18, 2019 02:00AM Mereo BioPharma Group plc ("Mereo" or the "Company" or the "Group") Merger Update: Acquisition of OncoMed Pharmaceuticals, Inc. ("OncoMed") – Result of OncoMe
Mar 5, 2019 08:30AM Mereo BioPharma to Present at the Cowen and Company 39th Annual Healthcare Conference on Tuesday, March 12, 2019
Jan 25, 2019 06:13AM Mereo Publicly Files Registration Statement on Form F-4 with U.S. Securities and Exchange Commission
Dec 10, 2018 02:00AM Mereo BioPharma to Present at The BMO Prescriptions for Success Healthcare Conference on 12 December 2018
Dec 5, 2018 08:10AM Proposed Combination of Mereo BioPharma and OncoMed Pharmaceuticals